本文選題：護(hù)心康片 + 穩(wěn)定型心絞痛�。� 參考：《湖南中醫(yī)藥大學(xué)》2016年碩士論文

【摘要】：目的:觀察評(píng)價(jià)護(hù)心康片聯(lián)合治療冠心病穩(wěn)定型心絞痛痰瘀互結(jié)證的臨床療效及安全性。方法:選取湖南省中醫(yī)藥大學(xué)第一附屬醫(yī)院穩(wěn)定型心絞痛痰瘀互結(jié)證住院患者60例,采用西雅圖生活量表評(píng)估研究對(duì)象生活質(zhì)量,依據(jù)隨機(jī)數(shù)字表法分為治療組和對(duì)照組,每組30例。治療前后填寫臨床觀察表,對(duì)照組常規(guī)西醫(yī)基礎(chǔ)治療,治療組在相同西醫(yī)基礎(chǔ)治療上加服護(hù)心康片,療程為4周。治療后記錄并分析比較兩組患者的心絞痛積分、硝酸甘油停減率、心電圖療效改善情況、中醫(yī)證候改善和中醫(yī)證候積分,及血脂變化水平、Duke評(píng)分和西雅圖生活量表評(píng)分。結(jié)果:(1)治療組和對(duì)照組均能改善患者臨床療效,治療組總有效率為90.0%,對(duì)照組為76.7%,且治療組改善臨床療效優(yōu)于對(duì)照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P0.05);(2)治療組和對(duì)照組均能改善患者心電圖,治療組總有效率為80.0%,對(duì)照組為63.3%,且治療組改善心電圖療效優(yōu)于對(duì)照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P0.05);(3)治療組和對(duì)照組均能改善患者心絞痛,治療組總有效率為86.7%,對(duì)照組為66.7%,且治療組改善心絞痛療效優(yōu)于對(duì)照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P0.05);(4)治療組和對(duì)照組均能改善患者硝酸甘油停減情況,治療組總有效率為90.0%,對(duì)照組為76.7%,且治療組改善硝酸甘油停減情況優(yōu)于對(duì)照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P0.05);(5)治療組和對(duì)照組均能改善患者中醫(yī)證候,治療組總有效率為90.0%,對(duì)照組為73.3%,且治療組改善中醫(yī)證候優(yōu)于對(duì)照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P0.05);(6)治療組和對(duì)照組均能調(diào)節(jié)患者血脂水平,治療前后比較差異有統(tǒng)計(jì)學(xué)意義(P0.05),治療后兩組血脂水平比較,治療組明顯優(yōu)于對(duì)照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P0.05);(7)治療組和對(duì)照組均能改善患者Duke評(píng)分及西雅圖生活量表評(píng)分,治療后兩組患者的Duke評(píng)分及西雅圖生活量表評(píng)分均有改觀,治療組改善效果優(yōu)于對(duì)照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P0.05);(8)安全性方面:治療前后兩組患者的血常規(guī)、電解質(zhì)及肝腎功能檢測(cè)結(jié)果均未出現(xiàn)明顯變化,且均未出現(xiàn)嚴(yán)重的不良反應(yīng),兩組組內(nèi)和組間比較均無統(tǒng)計(jì)學(xué)意義(P0.05),因此聯(lián)合護(hù)心康片與基礎(chǔ)西醫(yī)治療同樣具有良好的安全性。結(jié)論:護(hù)心康片聯(lián)合治療冠心病穩(wěn)定型心絞痛痰瘀互結(jié)證療效較單用基礎(chǔ)西藥治療優(yōu)勢(shì)明顯,并且能更有效改善患者血脂代謝功能,提高患者的Duke評(píng)分和生活質(zhì)量。
[Abstract]:Objective: to evaluate the efficacy and safety of Huxinkang tablet in treating stable angina pectoris with phlegm and blood stasis syndrome. Methods: sixty patients with stable angina pectoris and phlegm and blood stasis syndrome were selected from the first affiliated Hospital of Hunan University of traditional Chinese Medicine. The quality of life was evaluated by Seattle Life scale. The patients were randomly divided into treatment group and control group. There were 30 cases in each group. Before and after treatment, the clinical observation form was filled out, the control group was treated with routine western medicine, the treatment group was treated with Huxinkang tablet on the same basic western medicine treatment, the course of treatment was 4 weeks. After treatment, the angina pectoris score, the stopping rate of nitroglycerin, the improvement of electrocardiogram, the improvement of TCM syndromes, the score of TCM syndromes, the Duke score of blood lipid change and the score of Seattle Life scale were recorded and compared between the two groups. Results both the treatment group and the control group could improve the clinical efficacy. The total effective rate of the treatment group was 90.0 and that of the control group was 76.70.The improvement of the clinical efficacy of the treatment group was better than that of the control group. The electrocardiogram was improved in the treatment group and the control group. The total effective rate was 80.0 in the treatment group and 63.3 in the control group, and the effect of improving ECG in the treatment group was better than that in the control group. The total effective rate of treatment group was 86.7, and that of control group was 66.7.The curative effect of treatment group on angina pectoris was better than that of control group. The difference between the two groups was statistically significant (P 0.05). Both the treatment group and the control group could improve the total effective rate of nitroglycerin. The total effective rate of the treatment group was 90.0 and that of the control group was 76.7.The effect of the treatment group was better than that of the control group, and the improvement of the treatment group was better than that of the control group. The difference between the two groups was statistically significant (P 0.05) the treatment group and the control group could improve the TCM syndromes of the patients. The total effective rate of the treatment group was 90.0 and the control group was 73.3%, and the treatment group improved the TCM syndrome better than the control group. The difference between the two groups was statistically significant (P 0.05) treatment group and control group were able to regulate the level of blood lipid, and the difference before and after treatment was statistically significant (P 0.05). After treatment, the treatment group was significantly better than the control group. The difference between the two groups was statistically significant (P 0.05). Both the treatment group and the control group could improve the Duke score and the Seattle Life scale score. After the treatment, the Duke score and the Seattle Life scale score of the two groups were improved. The improvement effect of the treatment group was better than that of the control group, and the difference between the two groups was statistically significant (P 0.05). The results of blood routine, electrolytes and liver and kidney function of the two groups were not significantly changed before and after treatment. There were no serious adverse reactions in both groups and there was no significant difference between the two groups. Therefore, the combination of Huxinkang tablets and basic western medicine treatment had good safety. Conclusion: the therapeutic effect of Huxinkang tablet in treating stable angina pectoris with phlegm and blood stasis syndrome is more effective than that of western medicine alone, and it can improve the blood lipid metabolism function and improve the Duke score and quality of life of the patients.
【學(xué)位授予單位】：湖南中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R259

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 嚴(yán)茜;王瑞瑞;敖守良;屈波;;護(hù)心康片對(duì)動(dòng)脈粥樣硬化兔血脂及血漿ADMA的影響[J];中醫(yī)藥導(dǎo)報(bào);2015年08期

2 羅量;;冠心病治療方法的研究進(jìn)展[J];基層醫(yī)學(xué)論壇;2013年25期

3 屈波;蔡光先;董曉斐;劉柏炎;劉紅萍;;護(hù)心康對(duì)動(dòng)脈粥樣硬化兔TLR4mRNA的干預(yù)作用[J];中醫(yī)藥導(dǎo)報(bào);2013年02期

4 李新;朱瑩;楊暉;易健;劉崢嶸;謝勇;;護(hù)心康聯(lián)合靜脈骨髓間質(zhì)干細(xì)胞移植對(duì)急性心梗后大鼠心功能的影響[J];中醫(yī)藥導(dǎo)報(bào);2012年02期

5 屈波;蔡光先;劉柏炎;王桂棠;;護(hù)心康對(duì)動(dòng)脈粥樣硬化兔模型血脂的干預(yù)研究[J];實(shí)用預(yù)防醫(yī)學(xué);2007年03期

6 ;慢性穩(wěn)定性心絞痛診斷與治療指南[J];中華心血管病雜志;2007年03期

7 譚建平;蔡光先;毛惠瓊;;護(hù)心康片治療冠心病穩(wěn)定型心絞痛的療效觀察[J];中國現(xiàn)代醫(yī)學(xué)雜志;2005年23期

8 ;治療心病中成藥應(yīng)用指南[J];中國醫(yī)藥學(xué)報(bào);2004年10期

9 蔡光先,胡學(xué)軍,鄭愛華;護(hù)心康片治療冠心病心絞痛86例[J];中醫(yī)藥學(xué)刊;2003年03期

10 洪行球,沃興德,何一中,李萬里,高承賢,金明敏;半夏降血脂作用研究[J];浙江中醫(yī)學(xué)院學(xué)報(bào);1995年02期

，

本文編號(hào)：1882094